Onyx Shuts Down $10 Bln Offer - Presented by: The Aol. On Network

Shares of Onyx Pharmaceutical soaring after it received- and rejected a $10 billion takeover offer from biotech Amgen. Its shares were already up 31 percent over the past 12 months. Onyx says Amgen's offer of $120 a share is too low. That offer represents a premium of 38 percent based on Onyx's closing price on Friday. And Onyx may have a point. Deutsche Bank analyst Robin Karnauskas says in a note: "From our M&A valuation, we expect higher bids for Onyx of at least $140."



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 17.93 0.20 ▼ 1.10%
MU $ 18.72 1.18 ▼ 5.93%
FB $ 94.1844 1.03 ▼ 1.08%
AAPL $ 121.15 1.22 ▼ 1.00%
SUNE $ 23.40 2.23 ▼ 8.70%
F $ 14.76 0.34 ▼ 2.25%
VALE $ 5.22 0.03 ▲ 0.58%
ABX $ 7.075 0.03 ▲ 0.35%

As of 7/31/2015, 03:10 PM